Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Nivolumab 37pembrolizumab 26cabozantinib 26Specimen Handling 23Magnetic Resonance Spectroscopy 21Ipilimumab 19lenvatinib 13belzutifan 13Axitinib 13CTLA-4 Antigen 10Sunitinib 9Radiosurgery 8Biopsy 8atezolizumab 7fludarabine 4avelumab 4aldesleukin 4Immunoglobulin G 4Disulfides 4zimberelimab 3toripalimab 3tivozanib 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3Surveys and Questionnaires 3Nephrectomy 3Everolimus 3Cyclophosphamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Blood Cell Count × 90 days × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡